At a glance
ClinicalIndex Comparison RecordN/ACompleted· 250 enrolled
Drug / intervention
AbobotulinumtoxinAbiological
Likely dose
AbobotulinumtoxinA 0.25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Non-interventional Study to Collect Subject and Physician Satisfaction During Long Term Treatment of Glabellar Lines With Dysport® in Subjects of Chinese Origin in Real Clinical Practice
In Brief
An observational study evaluating AbobotulinumtoxinA for Glabellar Lines. Completed, enrolled 250 participants across 1 site.
Detailed Summary
This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartNov 2021
Primary CompletionSep 2023
Study CompletionDec 2023
TodayJul 2026
First PostedOct 22, 2021
Enrollment StartNov 11, 2021
Primary CompletionSep 12, 2023
Study CompletionDec 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.7 years ago
Interventions
AbobotulinumtoxinAbiological
Participants received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U \[0.05 mL per injection site\] of study drug into 5 injection sites intramuscularly.